Compass Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Yeah, no, chairs are a little rough. All right. Good morning, everyone. I'm Stephen Willey, one of the senior analysts here at Stifel. Glad to have with us in the next session, Tom Schuetz, who's the CEO of Compass Therapeutics. We're going to have a casual discussion. If anyone has a question, feel free to raise your hand. Tom, thanks for coming as always.
Sure. Thank you for having us.
Any opening statements you'd like to make before we jump right into Q&A?
Sure. Again, thanks for having us here. Always happy to come. For those of you who don't know, Compass, we're located in Boston. We're a monoclonal antibody discovery and development company in oncology. We've got four drugs in the clinic, which we'll talk about today. Our lead program, tovecimig, a couple of weeks ago, we presented data from a randomized trial at ESMO, and we simultaneously published all that data in the Journal of Clinical Oncology on October 24th. We're in the middle of re-engaging with FDA right now in order to have a conversation about a path forward to get this drug approved for the treatment of patients with biliary tract cancer.
Okay. And congrats on the JCO publication. I know that kind of puts a good bow on COMPANION-002.
Yeah. Thank you. Just curious, I know that there were kind of some incremental pieces of information that were disclosed and came out of both the presentation and the manuscript.
Anything you want to highlight there?
Sure. I think, interestingly, so you are correct, getting a publication in JCO simultaneously with an ESMO presentation does require some aligning of the planets.
Yeah. And, fascinatingly, during the review of the draft JCO manuscript, one of the reviewers specifically asked for the Two-Stage Estimation method to do the crossover correction on OS, and that, I think the question about the ITT analysis versus the crossover analysis, clearly showed that the hazard ratio is below one.
Yeah, but I think as you and I have talked about before, the intent to treat analysis is sort of anything but that.
The patients initially randomized to the control arm were not intended to be treated with tovecimig. That analysis is kind of irrelevant. It is really irrelevant. So, I think what we showed, not only in the JCO paper, but also in the ESMO presentation, the patients, if you got tovecimig at any time during this study, you lived longer. We need to just be clear about that and talk about that more clearly in our regulatory conversations.
Yep. Maybe this is a little bit too much of a statistically wonky question, but how does this second post-hoc analysis that was requested to look at the impact of patient crossover, how did that look, or how is that mechanistically or philosophically different from the rank-preserving model that you had pre-specified within the stats plan?
I am going to pounce on your use of the word wonky.
Okay if you don't mind.
Feel free. Because I'm not going to be fully able to go into that wonk.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
